H.C. Wainwright analyst Ed Arce maintained a Buy rating on Nabriva (NBRV) today and set a price target of $9. The company’s shares closed on Friday at $1.92, close to its 52-week low of $1.12.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.2% and a 36.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Nabriva has an analyst consensus of Moderate Buy, with a price target consensus of $12, implying a 525.0% upside from current levels. In a report issued on January 24, Needham also maintained a Buy rating on the stock with a $15 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.82 and a one-year low of $1.12. Currently, Nabriva has an average volume of 487.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic available for systemic administration in humans.
